|
Match
|
Document |
Document Title |
|
|
6927317 |
Modulating ramp activity
The invention provides genetically-modified non-human mammals and genetically-modified animal cells containing a disrupted RAMP1, RAMP2, or RAMP3 gene. Also provided by the invention are methods of...
|
|
|
6924415 |
Transgenic mice comprising a constitutively-activated MEK5 and exhibiting cardiac hypertrophy and dilated cardiomyopathy
The present invention relates to compositions and methods relating to MEK5 and its role in heart disease. This protein has now been identified as a target for therapeutic intervention due to its...
|
|
|
6924414 |
Muir-torre-like syndrome in Fhit deficient mice
The invention provides nonhuman transgenic animals with a disrupted FHIT gene. The invention further provides transgenic mice in which one or both Fhit alleles have been inactivated. Preferably,...
|
|
|
6924412 |
Means and methods for raising antibody concentration in compartments of the body of a non-human animal
Methods and processes for raising the concentration of a first class of immunoglobulin relative to at least a second class of immunoglobulin in a compartment of the body of a non-human animal or...
|
|
|
6921845 |
Use of animal model deficient in p53 and having memory deficiency and/or behavioral disorders for therapeutic purposes
Mice that are deficient in p53 are found to have memory disorders and/or behavioral disorders such as increased anxiety. A method of using p53-deficient mice to screen compounds for memory...
|
|
|
6921846 |
Antibody production methods relating to disruption of peripheral tolerance in B lympho-cytes
The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized animal having antibody-producing cells with disrupted peripheral tolerance. The...
|
|
|
6916654 |
Universal donor cells
Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells...
|
|
|
6909030 |
PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes
Disclosed is a null mutant (or knockout) rodent comprising in its germ cells an artificially induced PTTG null mutation. In some embodiments, the null mutant rodent can be generated by way of...
|
|
|
6909031 |
Transgenic mice containing glucagon receptor gene disruptions
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
6906238 |
Effective nuclear reprogramming in mammals using CDK2 inhibitors
The present invention provides methods of producing a cloned non-human mammalian nuclear transfer (NT) embryo and methods for producing a cloned non-human mammal. Embodiments of the methods include...
|
|
|
6891081 |
Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof
The present invention provides for a transgenic non-human animal whose cells contain a recombinant DNA sequence comprising a nerve tissue specific promoter operatively linked to a DNA sequence...
|
|
|
6891082 |
Transgenic non-human animals expressing a truncated activintype II receptor
The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In...
|
|
|
6888047 |
Transgenic animals as urinary bioreactors for the production of polypeptide in the urine, recombinant DNA construct for kidney-specific expression, and method of using same
The invention relates to recombinant DNA constructs, a method for producing a recombinant biologically active protein in vivo in the urine of a non-human mammal using a kidney-specific promoter,...
|
|
|
6872812 |
Hepp, a novel gene with a role in hematopoietic and neural development
The invention is directed to an isolated gene and protein product, designated Hepp, which has a role in mammalian hematopoiesis and neural function, and is further directed to a genetically...
|
|
|
6867348 |
Methods and compositions for screening for angiogenesis modulating compounds
The present invention relates to novel promoters, including transcription regulator regions, for the mouse VEGFR-2 receptor, isolated polynucleotides comprising such promoters, nucleic acid...
|
|
|
6864402 |
Chronic hepatitis virus infection and clonal hepatocellular carcinoma in mouse repopulated livers
A method is provided for repopulating degenerated of immunetolerant mice which lack mature B and T lymphocytes with xenogenic mammalian hepatocytes, particularly primate hepatocytes to generate...
|
|
|
6858772 |
Transgenic mice containing magnesium-dependent protein phosphatase gene disruptions
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
6858773 |
Transgenic mice comprising transcription control elements associated with mouse eosinophil peroxidase expression
The present invention relates to novel transcription control elements derived from a mouse eosinophil peroxidase gene. The novel transcription control elements described in the disclosure may...
|
|
|
6855545 |
Indexed library of cells containing genomic modifications and methods of making and utilizing the same
Methods and vectors (both DNA and retroviral) are provided for the construction of a Library of mutated cells. The Library will preferably contain mutations in essentially all genes present in the...
|
|
|
6838592 |
Methods for the identification of compounds for the treatment of alzheimer's disease
The invention features methods for identifying compounds useful for the treatment of Alzheimer's disease.
|
|
|
6835866 |
Compositions and methods of modulating cholesterol metabolism
The present invention relates to compositions and methods for reducing cholesterolemia and its effects. More specifically, the invention is directed, in one embodiment, to methods for screening for...
|
|
|
6828472 |
Inbred mouse strain selected for autoimmune arthritis
The present invention provides a mouse model with natural onset of morbid conditions strikingly similar to those of rheumatoid arthritis in humans. This mouse strain can be utilized as an animal...
|
|
|
6828473 |
Modulation of PDE11A activity
The invention provides genetically-modified non-human mammals and genetically-modified animal cells containing a functionally disrupted PDE11A gene. Also provided by the invention are methods of...
|
|
|
6825395 |
Transgenic non-human mammals expressing the human complement inhibitor (DAF/CD55)
This invention provides transgenic mammals other than man carrying the gene of the human complement inhibitor (DAF/CD55) and expressing the human complement inhibitor in their organs and tissues,...
|
|
|
6825394 |
Conditionally immortalized cell lines derived from transgenic animals
The invention relates to mammalian cell lines and transgenic mammals. More particularly, it relates to a method for producing a rat cell line, a method for producing a transgenic rat, a transgenic...
|
|
|
6822138 |
NIK-knockout mice
The present invention provides transgenic non-human mammals and cells having one or more structurally and functionally disrupted NIK alleles. In addition, the present invention provides methods for...
|
|
|
6815574 |
Methods of simulating human prostate cancer progression
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
|
|
|
6794132 |
Human antibodies
The invention uses the power of display selection methods to screen libraries of human immunoglobulin genes from nonhuman transgenic animals expresing human immunoglobulins. Such screening produces...
|
|
|
6794188 |
Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells and therapeutic uses thereof
Recombinant avian sarcoma leukosis virus (ASLV)-derived retrovirus vectors having an expanded host range are described. The host range is expanded by the replacement of the ASLV envelope gene by an...
|
|
|
6794186 |
pCAR and its uses
The invention provides improvements in the field of animal models for testing effects of genes introduced into animal cells or tissue by adenoviral gene transfer. More particularly the invention...
|
|
|
6791006 |
LKB1 gene knockout mice
A mammal is provided, in which the LKB1 gene can be deleted phase-specifically and tissue-specifically. These mammals are highly useful as tools to reveal the onset mechanism for diseases caused by...
|
|
|
6784335 |
Transgenic mice containing BMP gene disruptions
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
6784336 |
Method of producing mutant mice
A method of producing mutant/targeted non-human mammals, such as mutant mice that does not require production of chimera and permits the introduction of multiple mutations in embryos and, thus,...
|
|
|
6777235 |
Complementation trap
Methods and DNA constructs are provided for detection and manipulation of a target eukaryotic gene whose expression is restricted to certain tissues or specialized cell types. The methods include...
|
|
|
6774279 |
Use of FLP recombinase in mice
A method is disclosed for producing site-specific recombination of DNA in a transgenic non-human mammal at chromosomal regions containing Flp-recognition sites (e.g., a DNA sequence containing an...
|
|
|
6770797 |
Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid
The invention features a non-transgenic model of Alzheimer's Disease, method for inducing prolonged in vivo gene expression in a mammal, and methods of inhibiting Alzheimer's Disease-associated...
|
|
|
6765126 |
Transgenic mice containing NPY6-R neuropeptide receptor gene disruptions
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
6762342 |
Transgenic mice containing intestinal alkaline phosphatase gene disruptions
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
6762343 |
Mice with combined disruption of Gpx1 and Gpx2 genes have growth retardation, hypothermia, and colitis and provide a mouse model for cancer
Disclosed is a transgenic knockout mouse whose genome has a homozygous disruption in its endogenous Gpx1 and Gpx2 genes, wherein the disruptions result in a decrease in GPX activity in the...
|
|
|
6762341 |
Uses of mammalian CCR8 receptors and related reagents
Compositions and methods for using mammalian CCR8 receptor proteins, antagonists and related reagents to treat diseases or conditions associated with Th2-mediated responses in an individual,...
|
|
|
6753456 |
Point mutant mice with hypersensitive alpha 4 nicotinic receptors: dopaminergic pathology and increased anxiety
The present invention relates to transgenic animals expressing a hypersensitive nicotinic acetylcholine receptor. Transgenic animals have point mutations in the nucleic acid sequence encoding the...
|
|
|
6750375 |
Transgenic mouse comprising a disruption in an RGS9 gene
The invention relates to an animal model for studying behavior related to RGS9 and RGS9 modulated dopamine D2-mediated behavior. The invention provides transgenic non-human animals in which RGS9...
|
|
|
6743966 |
Production of membrane proteins in the milk of transgenic mammals
Production of proteins not normally secreted through conventional pathways such as membrane proteins including, for example, CFTR associated with cystic fibrosis, is now made possible by collection...
|
|
|
6743425 |
Therapeutic agents for achondroplasia
The present invention aims to provide novel therapeutic agents for achondroplasia caused by mutations in FGFR3. Therapeutic agents for achondroplasia caused by the cartilage growth inhibition...
|
|
|
6740793 |
Transgenic animal having a disrupted PDE7A gene and uses thereof
The present invention provides a transgenic non-human animal whose genome comprises a disruption in its endogenous PDE7A gene, wherein the transgenic animal exhibits decreased expression of...
|
|
|
6734337 |
Acetyl-coenzyme A carboxylase 2 as a target in the regulation of fat burning, fat accumulation, energy homeostasis and insulin action
The present invention highlights the role of acetyl-CoA carboxylase through its product malonyl-CoA in regulating fatty acid oxidation and synthesis, glucose metabolism and energy homeostasis. It...
|
|
|
6734336 |
Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring
The present invention provides a gene-targeted, non-human mammal having a gene encoding a mutant protein product of a mutated FAD presenilin-1 (PS-1) gene, a human FAD Swedish mutation, and a...
|
|
|
6730821 |
Transgenic mice containing retina-specific nuclear receptor gene disruptions
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic...
|
|
|
6727405 |
Transgenic animals secreting desired proteins into milk
A DNA sequence containing a gene encoding a protein, the gene being under the transcriptional control in the DNA sequence of a mammalian milk protein promoter which does not naturally control the...
|
|
|
6723893 |
Mice having a mutant SOD-1-encoding transgene
Disclosed is the family of genes responsible for the neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis. Methods and compounds for the diagnosis, prevention, and therapy of the...
|